| CytRx announced plans to initiate an open-label, multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a second-line treatment in patients with advanced gastric (stomach) cancer. Fifty patients with gastric cancer who have failed other treatments, including surgery and chemotherapy with drugs other than doxorubicin, will receive INNO-206 approximately every three weeks for four treatment cycles. Following trial initiation, recruitment of all patients is expected within approximately 12 months. Because the clinical trial will be open label, CytRx will be able to review data from the study on an ongoing basis. :theflyonthewall.com |
